No headlines found.
Globe Newswire (Tue, 7-May 12:28 PM ET)
PRNewswire (Tue, 7-May 11:30 AM ET)
Globe Newswire (Tue, 7-May 10:30 AM ET)
PRNewswire (Tue, 7-May 5:45 AM ET)
AVXL Investors Have Opportunity to Lead Anavex Life Sciences Corp. Securities Fraud Lawsuit
PRNewswire (Mon, 6-May 12:07 PM ET)
Globe Newswire (Mon, 6-May 12:07 PM ET)
PRNewswire (Mon, 6-May 5:45 AM ET)
Globe Newswire (Fri, 3-May 9:57 AM ET)
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Anavex
PRNewswire (Fri, 3-May 9:45 AM ET)
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.
Anavex Life Sciences Corp. trades on the NASDAQ stock market under the symbol AVXL.
As of May 7, 2024, AVXL stock price was flat at $3.84 with 810,833 million shares trading.
AVXL has a beta of 2.07, meaning it tends to be more sensitive to market movements. AVXL has a correlation of 0.15 to the broad based SPY ETF.
AVXL has a market cap of $315.21 million. This is considered a Small Cap stock.
In the last 3 years, AVXL stock traded as high as $31.50 and as low as $3.25.
The top ETF exchange traded funds that AVXL belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.
AVXL has underperformed the market in the last year with a return of -54.5%, while the SPY ETF gained +27.0%. In the last 3 month period, AVXL fell short of the market, returning -33.7%, while SPY returned +5.0%. However, in the most recent 2 weeks AVXL has outperformed the stock market by returning +4.3%, while SPY returned +3.5%.
AVXL support price is $3.67 and resistance is $4.01 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVXL stock will trade within this expected range on the day.